Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Haemonetics Corp Lowers FY 2013 Revenue Guidance; Reaffirms FY 2013 Earnings Guidance; Reaffirms FY 2014 Guidance


Wednesday, 30 Jan 2013 06:00am EST 

Haemonetics Corp announced that for fiscal 2013, it expects organic revenue growth to be approximate 4%, at the low end of the previous guidance range of 4%-6%. Thus, total revenue is estimated in the range of $888-$898 million for fiscal 2013, up 22-23%. Adjusted operating income of $127-$130 million is expected for fiscal 2013. Accordingly, the previously indicated adjusted earnings per share range of $1.65-$1.70, is reaffirmed. For fiscal 2014, previous indications are affirmed, as organic revenue growth is expected to approximate 5%-7%. Together with a full year of revenues from the acquired whole blood business, which is expected to contribute incremental revenue of $70 million related to the timing of the acquisition, fiscal 2014 revenue is expected to surpass $1 billion. The Company's previously provided preliminary outlook for fiscal 2014 adjusted earnings per share of $1.95-$2.05, approximately 20% above fiscal 2013 expected earnings per share, is affirmed. Included in these amounts are approximately $27 million or $0.35 per share of acquisition related amortization expense. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $900 million and EPS of $1.69 for fiscal 2013; revenue of $1.0 billion and EPS of $2.02 for fiscal 2014. 

Company Quote

35.88
-0.12 -0.33%
10:59am EDT